
Annual report 2021
added 10-13-2022
Qilian International Holding Group Limited Net Debt 2011-2026 | QLI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Qilian International Holding Group Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.3 M | -11.6 M | - | -1.04 M | 1.58 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.58 M | -11.6 M | -5.35 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.85 | 3.22 % | $ 9.26 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 330.55 | -0.85 % | $ 43.3 B | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
-132 M | $ 7.51 | 1.21 % | $ 74.2 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 21.68 | - | $ 1.01 B | ||
|
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | ||
|
BioNTech SE
BNTX
|
-973 M | $ 99.49 | 0.02 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 4.79 | 1.06 % | $ 771 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Cabaletta Bio
CABA
|
-76.6 M | $ 3.46 | 1.62 % | $ 348 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.17 | -2.16 % | $ 5.22 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
-6.03 M | - | -5.16 % | $ 5.39 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-133 M | $ 1.5 | -3.23 % | $ 386 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.24 | -0.12 % | $ 453 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.54 | -0.18 % | $ 3.12 B | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.48 | -1.01 % | $ 394 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-22.3 M | - | -16.75 % | $ 25.8 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Clearside Biomedical
CLSD
|
-27.9 M | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
-26.5 M | $ 33.97 | 0.3 % | $ 2.26 B | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
CNS Pharmaceuticals
CNSP
|
-13.6 M | $ 2.67 | -2.91 % | $ 1.18 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B |